Youngen Biotech Showcases at the 5th BIONNOVA Beijing Innovation Forum, Exploring a New Landscape for Extrahepatic Delivery of Small Nucleic Acid Drugs

On September 15, 2026, the 5th BIONNOVA Beijing Innovation Forum grandly opened in Beijing. The forum featured 13 thematic sessions covering cutting-edge tracks including antibodies, CGT (cell and gene therapy), small molecules, nucleic acids, and peptides, bringing together over a hundred expert speakers and more than 4,000 professional attendees to analyze core topics in innovative drug R&D and industrialization.


Youngen Biotech was invited to attend the conference. Dr. Gao Wei, the company's Chief Intellectual Property Officer, participated in on-site exchanges at the Nucleic Acid Drug R&D and Delivery Forum, engaging in in-depth discussions with industry peers on topics such as breakthroughs in extrahepatic delivery technology and the key bottlenecks for small nucleic acid drugs moving from the liver to systemic applications.

Extrahepatic Delivery: A Must-Win Battleground for Small Nucleic Acid Drugs to Reach Broader Markets

Small nucleic acid drugs are currently regarded as the third pharmaceutical revolution after small molecules and antibodies. Nucleic acid delivery technology is the key bottleneck for small nucleic acid drugs to move from the liver to the whole body, and from rare diseases to large chronic disease markets. Extrahepatic delivery determines whether small nucleic acids can truly cover broader therapeutic areas such as cardiovascular, central nervous system, adipose, and lung diseases. The main challenges currently faced lie in the distinct biological barriers of different tissues, the targeting efficiency of different delivery technologies, species differences in translating animal data to humans, and how to translate changes in biomarkers into genuine clinical benefit—these are obstacles that must be overcome in the journey from preclinical to clinical accessibility. Encouragingly, extrahepatic delivery is moving from proof-of-concept to clinical breakthroughs. Including Youngen Biotech's Kardia Shuttle^® myocardial delivery platform, delivery technologies are advancing from single liver targeting toward precise delivery to more tissues and organs.

Kardia Shuttle^®: A Technological Leap from Liver Targeting to Precise Myocardial Delivery

Youngen Biotech's Kardia Shuttle® platform, leveraging the TA-SEEK™ AI large model, has discovered the world's first target with high specific expression on the surface of myocardial cell membranes, enabling precise and targeted delivery of multiple modalities, including siRNA and ASO, to cardiac tissue. In terms of intellectual property, Youngen Biotech has completed a full-chain patent portfolio covering platform technologies, targeted small nucleic acids, and molecular synthesis processes.

Dr. Gao Wei stated: "Whoever first breaks through the core bottleneck of extrahepatic delivery will dominate the next-generation small nucleic acid industry landscape." He believes that Youngen Biotech's Kardia Shuttle® myocardial delivery platform has demonstrated extremely high delivery efficiency and safety in preclinical studies. As a universal technology platform, Kardia Shuttle^® possesses strong potential for target and indication expansion. Combined with the R&D team's deep understanding of cardiac diseases and precise target selection, it will greatly advance the treatment of cardiac diseases and meet patients' expectations for safer and more effective innovative therapies.

At this BIONNOVA Forum, breakthroughs in delivery technology for small nucleic acid drugs became one of the focal points of discussion among attending experts. In addition to cardiac-targeted delivery, directions such as CNS delivery and muscle delivery are also accelerating validation. An industry consensus is forming: generational breakthroughs in delivery technology will redraw the competitive tiers of the small nucleic acid industry.

Youngen Biotech's deep participation in this high-level industry forum not only demonstrates the company's independent innovation capabilities in the field of extrahepatic delivery, but also reflects the industrial determination of Chinese small nucleic acid companies to move from "following" to "leading." With the continued validation and clinical advancement of extrahepatic delivery platforms such as Kardia Shuttle®, the therapeutic landscape of small nucleic acid drugs is expected to expand from the liver to broader tissues and organs, bringing long-acting, convenient, and novel treatment options to patients with chronic diseases such as cardiovascular and metabolic disorders.